Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Krystal Biotech, Inc.

http://www.krystalbio.com/

Latest From Krystal Biotech, Inc.

Nine Endocrine And Metabolic Disease Drug Launches To Look Out For In 2022

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.

Approvals Companies

Analysts Impressed By Amryt As EB Drug Action Date Approaches

Amryt has set out its future plans to the investment community with much depending on the successful relaunch of its just-acquired acromegaly drug Mycapssa and a potential FDA approval for its epidermolysis bullosa gel Filsuvez.

Business Strategies Rare Diseases

US FDA’s Botanical Drugs Guidance Will See Rare Outing For Amryt’s Filsuvez NDA

Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.

Drug Approval Standards Drug Review

Butterfly Skin Therapy Pipeline Primed For Transformation

No drugs are approved for epidermolysis bullosa and children with so-called butterfly skin are currently treated by cleaning open wounds and bandaging them. This could soon change.

Dermatology Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Topical Delivery
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
UsernamePublicRestriction

Register